Bayer (FRA:BAYN) Given a €124.00 Price Target at Commerzbank

Commerzbank set a €124.00 ($153.09) price target on Bayer (FRA:BAYN) in a report released on Tuesday, January 9th. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other research analysts also recently commented on BAYN. Baader Bank set a €120.00 ($148.15) price objective on Bayer and gave the stock a neutral rating in a research note on Wednesday, September 13th. UBS Group set a €125.00 ($154.32) price objective on Bayer and gave the stock a buy rating in a research note on Wednesday, September 13th. JPMorgan Chase & Co. reissued a buy rating on shares of Bayer in a research note on Wednesday, September 13th. Independent Research set a €120.00 ($148.15) target price on Bayer and gave the company a neutral rating in a research note on Wednesday, September 13th. Finally, Warburg Research set a €121.00 ($149.38) target price on Bayer and gave the company a buy rating in a research note on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. Bayer has an average rating of Buy and an average target price of €121.71 ($150.26).

Bayer (FRA BAYN) opened at €102.12 ($126.07) on Tuesday. The stock has a market capitalization of $84,120.00 and a PE ratio of 24.14. Bayer has a 12-month low of €101.45 ($125.25) and a 12-month high of €123.82 ($152.86).

ILLEGAL ACTIVITY NOTICE: “Bayer (FRA:BAYN) Given a €124.00 Price Target at Commerzbank” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/02/bayer-bayn-given-a-124-00-price-target-by-commerzbank-analysts.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply